Closing the data loop in AI-driven drug discovery

Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law.

AI developments move capital, regulation, and competitive advantage across the tech stack.

MIT Technology Review AI reported on this under ai. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.